Pre-Made Ensovibep biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting Severe acute respiratory syndrome coronavirus 2 RBD for drug discovery and mechanism of action (MOA) research

Pre-Made Ensovibep biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting Severe acute respiratory syndrome coronavirus 2 RBD is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ensovibep is a DARPin therapeutic candidate, designed specifically to inhibit target cell entry of SARS-CoV-2, the virus that causes COVID-19. DARPins (Designed Ankyrin Repeat Proteins) are mono or multi-specific protein-based therapies, designed to specifically engage their targets for various effects. Ensovibep includes three covalently linked individual DARPin domains which bind to the spike protein of SARS-CoV-2. With these domains incorporated into a single molecule, ensovibep is designed to block the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, even in the presence of some mutations of the spike protein. Several characteristics of DARPin therapeutics make them potentially suitable for COVID-19 treatment, including multi-specific binding, the rapid onset of action, and scalable bacterial production.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-837-1mg	1mg	3090
GMP-Bios-INN-837-10mg	10mg	Inquiry
GMP-Bios-INN-837-100mg	100mg	Inquiry
GMP-Bios-INN-837-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Ensovibep biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting Severe acute respiratory syndrome coronavirus 2 RBD
INN Name	Ensovibep
Target	Severe acute respiratory syndrome coronavirus 2 RBD
Format	Recombinant Protein
Derivation	synthetic construct
Species Reactivity	human
CH1 Isotype	Alternative to antigen receptors (domain scaffold: ANK, ankyrin repeats) 5 ANK domains
VD LC	Alternative to antigen receptors (domain scaffold: ANK, ankyrin repeats) 5 ANK domains
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Molecular Partners (Switzerland)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	Alternative to antigen receptors, domain scaffold ANK, ankyrin repeats (DARPin®)